FGF9 Polyclonal antibody

FGF9 Polyclonal Antibody for IHC, IF/ICC, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

IHC, IF/ICC, ELISA

Conjugate

Unconjugated

Cat no : 26554-1-AP

Synonyms

FGF-9, FGF 9, Heparin-binding growth factor 9, HBGF-9, Glia-activating factor


☆大好評トライアルサイズ ¥20,000~! >>> 一次抗体特別価格キャンペーン開催中!


Tested Applications

Positive IHC detected inhuman stomach tissue, human prostate cancer tissue, human colon cancer tissue, human small intestine tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF/ICC detected inMCF-7 cells

Recommended dilution

ApplicationDilution
Immunohistochemistry (IHC)IHC : 1:50-1:500
Immunofluorescence (IF)/ICCIF/ICC : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

26554-1-AP targets FGF9 in IHC, IF/ICC, ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen FGF9 fusion protein Ag24244 相同性解析による交差性が予測される生物種
Full Name fibroblast growth factor 9 (glia-activating factor)
Calculated molecular weight 208 aa, 23 kDa
GenBank accession numberBC069692
Gene symbol FGF9
Gene ID (NCBI) 2254
RRIDAB_2880550
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

Fibroblast growth factor 9 (FGF9) is a critically important and elegantly regulated growth factor that was first identified during a screen for factors acting on cells of the central nervous system (CNS). Over the subsequent two decades of research, FGF9 has been revealed to play a significant role in various biological processes. A key feature of its control is reciprocal compartmentalization, particularly during development, with the epithelium serving as a dominant source and mesenchyme as a prime target. This mesenchyme selectivity is achieved through the high affinity of FGF9 to the IIIc isoforms of FGFR1, 2, and 3. FGF9 is widely expressed in the embryo, including in the developing heart and lungs, and more selectively in adult tissues, such as the CNS and kidneys.

Protocols

Product Specific Protocols
IHC protocol for FGF9 antibody 26554-1-APDownload protocol
IF protocol for FGF9 antibody 26554-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols